Vivos Therapeutics, Inc. (VVOS)
Nasdaq · Healthcare · Medical Devices
$0.1541+1.52%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $5.2M
- 52-week range
- $0.129 – $3.35
- 52-week change
- −95.10%
- EPS (trailing)
- −$1.91
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $17.4M (+16.05%)
- Net income
- −$21.2M
- Operating margin
- −114.1%
- Diluted EPS
- −$2.07
- Free cash flow
- −$17.6M
From the company’s annual report on SEC EDGAR.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Headquarters: Littleton, United States · 268 employees · vivos.com